-
1.发明申请COMPOSITIONS AND METHODS FOR TREATING HEMATOLOGIC CANCERS TARGETING THE SIRPα - CD47 INTERACTION 审中-公开用于治疗靶向SIRPa-CD47相互作用的血液癌的组合物和方法
公开(公告)号：WO2010130053A1
公开(公告)日：2010-11-18
申请号：PCT/CA2010/000743
申请日：2010-05-14
Applicant: UNIVERSITY HEALTH NETWORK , THE HOSPITAL FOR SICK CHILDREN , WANG, C. Y., Jean , DICK, John , DANSKA, Jayne , JIN, Liqing , PRASOLAVA, Tatiana , THEOCHARIDES, Alexandre
Inventor： WANG, C. Y., Jean , DICK, John , DANSKA, Jayne , JIN, Liqing , PRASOLAVA, Tatiana , THEOCHARIDES, Alexandre
CPC classification number: C12Q1/6886 , A61K38/16 , C12Q2600/156
Abstract: The invention relates to modulating the SIRPα-CD47 interaction in order to treat hematological cancer and compounds therefor. In some embodiments, there is provided methods and uses of SIRPα polypeptides, fragments and fusion proteins for treating hematological cancer, preferably human acute myeloid leukemia.
Abstract translation: 本发明涉及调节SIRPa-CD47相互作用以治疗血液癌症及其化合物。 在一些实施方案中，提供了用于治疗血液癌症，优选人急性骨髓性白血病的SIRA2多肽，片段和融合蛋白的方法和用途。
-
公开(公告)号：WO2017132749A1
公开(公告)日：2017-08-10
申请号：PCT/CA2017/000025
申请日：2017-02-06
Applicant: UNIVERSITY HEALTH NETWORK
Inventor： WANG, Jean , DICK, John , NG, Stanley , MINDEN, Mark , MITCHELL, Amanda , CHEN, Weihsu, Claire , ZANDSTRA, Peter , KENNEDY, James
CPC classification number: G01N33/57426 , C12Q1/6883 , C12Q2600/106 , C12Q2600/118 , C12Q2600/158 , C40B40/06 , C40B40/08 , G01N2800/52 , G06F19/10 , G06F19/20
Abstract: There is described herein a method of prognosing or classifying a subject with acute myeloid leukemia (AML) comprising: (a) determining the expression level of at least 3 genes in a test sample from the subject selected from the group consisting of DNMT3B, ZBTB46, NYNRIN, ARHGAP22, LAPTM4B, MMRN1, DPYSL3, KIAAQ125. CDK6, CPXM1, SOCS2, SMIM24, EMP1, NGFRAP1, CD34, AKR1C3, GPR56; and (b) comparing expression of the at least 3 genes in the test sample with reference expression levels of the at least 3 genes from control samples from a cohort of patients; wherein a difference or similarity in the expression of the at least 3 genes in the test sample and the reference expression levels is used to prognose or classify the subject with AML into a low risk group or a high risk group for worse survival.
Abstract translation: 本文描述了预测或分类患有急性骨髓性白血病（AML）的受试者的方法，其包括：（a）确定来自选自以下的对象的测试样品中的至少3个基因的表达水平： 由DNMT3B，ZBTB46，NYNRIN，ARHGAP22，LAPTM4B，MMRN1，DPYSL3，KIAAQ125组成的组。 CDK6，CPXM1，SOCS2，SMIM24，EMP1，NGFRAP1，CD34，AKR1C3，GPR56; 和（b）比较测试样品中至少3种基因的表达与来自一组患者对照样品的至少3种基因的参考表达水平; 其中使用测试样品中至少3种基因的表达和参考表达水平的差异或相似性来预测或分类具有AML的受试者成为低风险组或高风险组以生存更差。
-
3.发明申请SELF-RENEWING SINGLE HUMAN HEMATOPOIETIC STEM CELLS, AN EARLY LYMPHOID PROGENITOR AND METHODS OF ENRICHING THE SAME 审中-公开自我修复单个人类HEMATOPOIETIC干细胞，早期淋巴细胞发生子及其增强方法
公开(公告)号：WO2011041912A1
公开(公告)日：2011-04-14
申请号：PCT/CA2010/001625
申请日：2010-10-08
Applicant: UNIVERSITY HEALTH NETWORK , DICK, John , NOTTA, Faiyaz , DOULATOV, Sergei , LAURENT, Elisa
Inventor： DICK, John , NOTTA, Faiyaz , DOULATOV, Sergei , LAURENT, Elisa
IPC: C12N5/0789 , C12N5/078 , C12N5/0784
CPC classification number: C12N5/0647
Abstract: This invention relates to human hematopoietic stem cells. Specifically the invention relations to the identification of single human hematopoietic stem cells capable of long- term multilineage engraftment and self-renewal. The invention also relates to an early lymphoid progenitor with monocytic potential, including dendritic cell potential.
Abstract translation: 本发明涉及人类造血干细胞。 具体地说，本发明与鉴定能够长期多系植入和自我更新的单人造血干细胞的关系。 本发明还涉及具有单核细胞电位的早期淋巴样祖细胞，包括树突状细胞电位。
-
4.发明申请ANTIBODIES AND ANTIBODY FRAGMENTS TARGETING SIRP-ALPHA AND THEIR USE IN TREATING HEMATOLOGIC CANCERS 审中-公开靶向SIRP-ALPHA的抗体和抗体片段及其在治疗肝癌中的应用
公开(公告)号：WO2013056352A1
公开(公告)日：2013-04-25
申请号：PCT/CA2012/000964
申请日：2012-10-19
Applicant: UNIVERSITY HEALTH NETWORK , THE HOSPITAL FOR SICK CHILDREN , WANG, Jean C. Y. , DANSKA, Jayne S. , DICK, John , SIDHU, Sachdev , UPPALAPATI, Maruti
Inventor： WANG, Jean C. Y. , DANSKA, Jayne S. , DICK, John , SIDHU, Sachdev , UPPALAPATI, Maruti
CPC classification number: C07K16/18 , C07K14/70503 , C07K16/2803 , C07K2317/33 , C07K2317/565 , C07K2317/73 , C07K2317/76 , C07K2317/92 , C07K2319/31 , C12Y301/03048
Abstract: The invention relates to modulating the SIRP α - CD47 interaction in order to treat hematological cancer and compounds therefor. In particular, there is also provided SIRP α antibodies and antibody fragments, preferably used for treating hematological cancer.
Abstract translation: 本发明涉及调节SIRPalpha-CD47相互作用以治疗血液癌症及其化合物。 特别地，还提供了SIRPalpha抗体和抗体片段，优选用于治疗血液癌症。
-
5.发明申请USE OF MIR-126 FOR ENHANCING HEMATOPOIETIC STEM CELL ENGRAFTMENT, FOR ISOLATING HEMATOPOIETIC STEM CELLS, AND FOR TREATING AND MONITORING THE TREATMENT OF ACUTE MYELOID LEUKEMIA 审中-公开使用MIR-126来增强HEMATOPOIETIC STEM CELL ENGRAFTMENT，用于分离HEMATOPOIETIC STEM细胞，并用于治疗和监测急性髓性白血病的治疗
公开(公告)号：WO2010051639A1
公开(公告)日：2010-05-14
申请号：PCT/CA2009/001612
申请日：2009-11-06
Applicant: UNIVERSITY HEALTH NETWORK , DICK, John , LECHMAN, Eric , HOPE, Kristin , HIRAMATSU, Hidefumi
Inventor： DICK, John , LECHMAN, Eric , HOPE, Kristin , HIRAMATSU, Hidefumi
CPC classification number: C12N15/113 , C12N2310/113 , C12N2310/141 , C12N2310/315 , C12N2310/321 , C12N2310/3515 , C12N2740/15043 , C12N2310/3521
Abstract: There is disclosed herein composition, methods and uses relating to miR-126 as a measure of engraftment potential of a population of hematopoietic stem cells (HSCs), as a method of purifying HSCs and in the monitoring or treatment of acute myeloid leukemia.
Abstract translation: 本文公开了与miR-126相关的组成，方法和用途，作为造血干细胞群体（HSC）的移植潜力的量度，作为纯化HSC的方法以及监测或治疗急性骨髓性白血病。
-
Patent Agency Ranking
公开(公告)号：WO2022109737A1
公开(公告)日：2022-06-02
申请号：PCT/CA2021/051683
申请日：2021-11-24
Applicant: UNIVERSITY HEALTH NETWORK
Inventor： XIE, Stephanie , DICK, John
IPC: A61K31/661 , A61K31/137 , A61P35/00 , A61P35/02 , C40B30/04 , C12Q1/6809 , G01N33/574
Abstract: There is described herein methods of treating a hematological cancer in a patient, the method comprising administering to the patient a therapeutically effective amount of a sphingosine-1-phosphate pathway modulator.
-
公开(公告)号：WO2017190214A1
公开(公告)日：2017-11-09
申请号：PCT/CA2017/000107
申请日：2017-05-03
Applicant: UNIVERSITY HEALTH NETWORK
Inventor： DICK, John , XIE, Stephanie , LAURENTI, Elisa , PRAT, Laura Garcia , FERRARI, Robin Thomas
IPC: C12N5/0789 , C12N5/02 , C12N5/078
Abstract: There is described herein a method for improving or preserving hematopoietic stem cell (HSC) self-renewal during ex-vivo expansion of a population of cells comprising HSCs in an expansion medium, the method comprising culturing the population of cells in the presence of N-(4hydroxyphenyl)retinarnide (4HPR).
Abstract translation: 本文描述了在扩增培养基中包含HSC的细胞群离体扩增期间改善或保存造血干细胞（HSC）自我更新的方法，所述方法包括培养群体 细胞在N-（4-羟基苯基）视黄酰胺（4HPR）存在下。
-
8.发明申请LSC AND HSC SIGNATURES FOR PREDICTING SURVIVAL OF PATIENTS HAVING HEMATOLOGICAL CANCER 审中-公开LSC和HSC标志物预测患有病理性癌症的患者存活
公开(公告)号：WO2011066660A1
公开(公告)日：2011-06-09
申请号：PCT/CA2010/002048
申请日：2010-12-03
Applicant: UNIVERSITY HEALTH NETWORK , THE HOSPITAL FOR SICK CHILDREN , THE BRIGHAM AND WOMEN'S HOSPITAL, INC. , DICK, John , EPPERT, Kolja , JURISICA, Igor , WALDRON, Levi David , MINDEN, Mark , LECHMAN, Eric , NILSSON, Bjorn , EBERT, Benjamin Levine , TAKENAKA, Katsuto , DANSKA, Jayne S.
Inventor： DICK, John , EPPERT, Kolja , JURISICA, Igor , WALDRON, Levi David , MINDEN, Mark , LECHMAN, Eric , NILSSON, Bjorn , EBERT, Benjamin Levine , TAKENAKA, Katsuto , DANSKA, Jayne S.
CPC classification number: C12Q1/6881 , C12Q1/6886 , C12Q2600/118 , C12Q2600/158 , C12Q2600/16 , G01N33/57426 , G01N2800/56 , G06F19/20 , G06F19/24
Abstract: A method for determining prognosis in a subject having a hematological cancer comprising: a) determining an expression profile by measuring the gene expression levels of a set of genes selected from a leukemic stem cell (LSC) gene signature marker set or an hematopoietic stem cell (HSC) gene signature marker set, in a sample from a subject; and b) classifying the subject as having a good prognosis or a poor prognosis based on the expression profile; wherein a good prognosis predicts an increased likelihood of survival within a predetermined period after initial diagnosis and poor prognosis predicts a decreased likelihood of survival within the predetermined period after initial diagnosis.
Abstract translation: 一种用于确定具有血液癌症的受试者的预后的方法，包括：a）通过测量选自白血病干细胞（LSC）基因特征标志物组或造血干细胞（LSC）基因组的基因集合的基因表达水平来确定表达谱， HSC）基因签名标记集，来自受试者的样本; 和b）基于表达谱，将受试者分类为具有良好的预后或不良预后; 其中良好的预后预测在初始诊断之后的预定时间段内增加的存活可能性，并且不良预后预测在初始诊断之后的预定时间段内生存的可能性降低。
-
公开(公告)号：EP3452581A1
公开(公告)日：2019-03-13
申请号：EP17792305.9
申请日：2017-05-03
Applicant: University Health Network
Inventor： DICK, John , XIE, Stephanie , LAURENTI, Elisa , PRAT, Laura Garcia , FERRARI, Robin Thomas
IPC: C12N5/0789 , C12N5/02 , C12N5/078
-
公开(公告)号：EP3411517A1
公开(公告)日：2018-12-12
申请号：EP17746659.6
申请日：2017-02-06
Applicant: University Health Network
Inventor： WANG, Jean , DICK, John , NG, Stanley , MINDEN, Mark , MITCHELL, Amanda , CHEN, Weihsu, Claire , ZANDSTRA, Peter , KENNEDY, James
CPC classification number: G01N33/57426 , C12Q1/6883 , C12Q2600/106 , C12Q2600/118 , C12Q2600/158 , C40B40/06 , C40B40/08 , G01N2800/52 , G06F19/10 , G06F19/20
Abstract: There is described herein a method of prognosing or classifying a subject with acute myeloid leukemia (AML) comprising: (a) determining the expression level of at least 3 genes in a test sample from the subject selected from the group consisting of DNMT3B, ZBTB46, NYNRIN, ARHGAP22, LAPTM4B, MMRN1, DPYSL3, KIAAQ125. CDK6, CPXM1, SOCS2, SMIM24, EMP1, NGFRAP1, CD34, AKR1C3, GPR56; and (b) comparing expression of the at least 3 genes in the test sample with reference expression levels of the at least 3 genes from control samples from a cohort of patients; wherein a difference or similarity in the expression of the at least 3 genes in the test sample and the reference expression levels is used to prognose or classify the subject with AML into a low risk group or a high risk group for worse survival.
-
-
-
-
-
-
-
-
-
Search Results
14
records
(took 0.028 seconds)
